Moreover, I was pleasantly surprised that neither it's up to $2 billion deal with United Biotechnology to develop UBT251 [GLP-1/GIP/GCG triagonist] for the treatment of cardiometabolic diseases ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

The company agreed to pay up to $2 billion for the rights to UBT251, a developmental weight-loss and obesity drug from Chinese pharmaceutical company United Bio-Technology (Hengqin), as it looks ...

UBT251 Injection* UBT251 Injection* Anti - IL - 4Ra / TSLP Bispecific Antibody* Osteoporosis TUL01101 Tablets* Rheumatoid Arthritis TUL01101 Ointment* Atopic Dermatitis Demodex Blepharitis LB2149 ...

UBT251 is a long-acting GLP-1/GIP/GCG triple- target receptor agonist with potent activity against glucagon-like peptide-1 (GLP-1), glucose- dependent insulinotropic polypeptide (GIP), and glucagon ...

BMO maintains Novo Nordisk stock Outperform rating, $105 target ...

Visit a quote page and your recently viewed tickers will be displayed here.